English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAntibiotic sales soared during India’s first surge of COVID-19, suggesting that the drugs were inappropriately used to treat mild and moderate COVID-19 infections, according to research led by Washington University School of Medicine in St. Louis. The excessive usage is especially concerning because antibiotic overuse increases the risk for drug-resistant infections — not just in India, but worldwide.
Tag: Azithromycin
Potential COVID-19 drug azithromycin may increase risk for cardiac events
Azithromycin — a commonly-prescribed antibiotic — also is being investigated as a potential treatment for COVID-19. Researchers have found that azithromycin by itself is not associated with an increase in cardiac events; however, if the drug is taken with certain other drugs that affect the electrical functioning of the heart, then cardiac events increased.
First Do No Harm – Researchers Urge Halt in Prescribing Hydroxycholoroquine for COVID-19
Researchers urge a moratorium on prescribing chloroquine or hydroxychloroquine, with or without azithromycin, to treat or prevent COVID-19, and caution that the reassuring safety profile of hydroxychloroquine may be more apparent than real. Safety data derive from decades of prescriptions by clinicians, primarily for their patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle age women, who are at very low risk of fatal heart outcomes due to hydroxychloroquine.
Larger study to test combination treatment for COVID-19
A study is now enrolling participants to determine whether a treatment combining a low dose of hydroxychloroquine and azithromycin can prevent hospitalization and death in people with COVID-19.
Dr. Ann Collier, professor of medicine, Division of Allergy and Infectious Diseases at the University of Washington School of Medicine, explains the national study is looking to enroll 2,000 patients at sites across the country.
ACTG Launches Clinical Trial Testing Treatment for COVID-19
The AIDS Clinical Trials Group (ACTG) has initiated a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19.
University of Kentucky Launches Clinical Trial to Evaluate New Treatments for COVID-19
Clinical leaders from the University of Kentucky’s Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.
Two Major COVID-19 Clinical Trials Launched to Determine Effectiveness and Safety of Drugs in Treating Coronavirus
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs – hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19.
University of Utah Health and Intermountain Healthcare Launch Two COVID-19 Clinical Trials to Test Effectiveness of Drugs
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs –hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19 (infection with the novel coronavirus).